KPV Peptide Dosage & Reconstitution Guide (Anti-Inflammatory Protocol)
KPV
KPV (Lys-Pro-Val) is a tripeptide fragment derived from the C-terminal region of α-MSH (alpha-melanocyte-stimulating hormone). Preclinical research has studied KPV for anti-inflammatory activity, including effects on NF-κB signaling, with particular interest in intestinal inflammation, skin, and inflammatory regulation. Human clinical evidence remains very limited.
How It Works
NF-κB ↓ → Inflammation ↓ → Gut + Skin + Tissue Support
Preclinical research suggests KPV can influence inflammatory pathways, including NF-κB signaling, and has been studied for potential effects on intestinal inflammation, skin, and tissue responses. Unlike anabolic or growth-hormone-related peptides, KPV is primarily researched for its anti-inflammatory activity.
Typical Injectable Research-Use Protocol
10 mg Vial + 3.0 mL BAC Water → 1 Unit = 33.3 mcg → Gradual Inflammation Support
Standard Setup
Vial
10 mg
Water
3.0 mL bacteriostatic water
Concentration
3.33 mg/mL
Conversion
1 unit = 33.3 mcg
Weeks 1–2
Starting Range
Dose
250 mcg
Units
7.5 units
Volume
0.075 mL
Frequency
Once daily
Weeks 3–8
Standard Range
Dose
500 mcg
Units
15 units
Volume
0.15 mL
Frequency
Once daily
Optional Higher Research Range
Higher Range
Dose
750–1,000 mcg
Units
22.5–30 units
Volume
0.225–0.30 mL
Frequency
Once daily
This higher range is discussed in research and peptide-use communities but is not supported by a validated human KPV dosing standard.
Optional Maintenance
Only If Needed
Dose
250–500 mcg
Units
7.5–15 units
Frequency
Once daily
Duration
2–4 additional weeks if needed
Protocol clarity
KPV does not have an established FDA-approved or clinically validated human dosing protocol. The standard framework shown here keeps the primary range at 250–500 mcg once daily. Higher ranges are separated rather than treated as a required step, and maintenance is optional rather than an automatic taper.
Research Status: No standardized human KPV dosing regimen has been established. The injectable schedule shown here reflects commonly discussed research-use protocols rather than a clinically validated dosing guideline.
KPV does not have an established FDA-approved or clinically validated human dosing protocol. The standard framework shown here keeps the primary range at 250–500 mcg once daily. Higher ranges are separated rather than treated as a required step, and maintenance is optional rather than an automatic taper.
Research Status: No standardized human KPV dosing regimen has been established. The injectable schedule shown here reflects commonly discussed research-use protocols rather than a clinically validated dosing guideline.
How to Use KPV (Cycle, Timing & Injection)
Frequency
Once daily
Typical Cycle
6–8 weeks
Optional Maintenance
2–4 additional weeks
Injection TypeSubcutaneous
Common SitesAbdomen, thigh, upper arm
TimingUse at a consistent time daily
Best Time to Take
Consistent timing matters more than the exact time of day.
Morning or evening can be used depending on what is easiest to repeat daily.
For gut or inflammation-focused routines, using it at the same time daily makes tracking response easier.
Where to Inject
Subcutaneous injection is the common route discussed.
Abdomen, thigh, and upper arm are common injection sites.
Rotate injection sites regularly, especially during longer inflammation-support phases.
When to Use
During gut-support phases
During inflammation-focused phases
During skin or tissue-calming support phases
As a targeted support phase rather than a strong anabolic or hormonal protocol
Simple Strategy
Use in Phases
KPV is usually best framed as an inflammation-control support phase, not a “more is better” peptide.
Goal-Based Research
KPV is primarily studied in inflammation-related models, including intestinal, skin, and tissue inflammatory pathways. Research-use protocols are generally structured around these areas of interest rather than anabolic or hormonal effects.
Reconstitution & Dosing (10 mg Vial)
Reconstitution & Dosing
Vial10 mg
Water3.0 mL
Concentration3.33 mg/mL
Conversion1 unit = 33 mcg
Dose Reference
7.5 units = about 250 mcg
15 units = about 500 mcg
22.5 units = about 750 mcg
30 units = about 1,000 mcg
Reconstitution Steps
Draw 3.0 mL bacteriostatic water
Inject slowly down the vial wall
Gently swirl, do not shake
Allow powder to fully dissolve
Storage & Shelf Life
Storage & Shelf Life
Lyophilized (unmixed)
Refrigerated (2–8°C): ~12–24 months
Frozen (−20°C): up to ~2–3 years
Store sealed, dry, and protected from light
Reconstituted (mixed)
Refrigerated (2–8°C): about 4 weeks typical use window
Do not freeze after mixing
Avoid repeated temperature changes
Best Practice
Handling
Keep the vial cold, protected from light, and limit unnecessary handling.
Visual Check
If the solution becomes cloudy, discolored, or contains visible particles, it is safer not to continue using it.
Time Between Cycles
Support Phase → Reset → Support Again if Needed
Standard Time Between Cycles
Cycle Length8–12 weeks
Time Off2–4 weeks
Why taper back down?
The lower maintenance phase shown here is a research-use protocol structure rather than a clinically established requirement. There is currently no human evidence demonstrating that KPV must be tapered or that a maintenance phase is necessary.
The lower maintenance phase shown here is a research-use protocol structure rather than a clinically established requirement. There is currently no human evidence demonstrating that KPV must be tapered or that a maintenance phase is necessary.
Best Ways to Structure It
Option 18–12 weeks on, 2–4 weeks off
Best standard structure for longer gut or inflammation phases
Option 2Shorter targeted support phase
Useful if running it only during a flare or recovery window
When to Stop Sooner
Symptoms have clearly stabilized
No added benefit is noticeable anymore
You are continuing without a clear reason or support goal
Monitoring During Use
Inflammation levels
Gut symptoms
Skin condition
Overall recovery
Potential / Studied Effects
Studied for anti-inflammatory activity and NF-κB signaling
Studied in preclinical models of intestinal inflammation
May influence inflammatory signaling involved in skin and tissue responses
Has demonstrated anti-inflammatory effects in laboratory and animal research
Potential Side Effects
Injection-site irritation or sensitivity may occur with injectable use
Human safety data for injectable KPV remain very limited
Long-term safety and adverse-effect frequency have not been established in controlled human studies
Commonly Discussed Research Combinations
KPV → Inflammation Control
BPC-157 → Healing Support
GHK-Cu → Tissue Repair
BPC-157 → Healing Support
GHK-Cu → Tissue Repair
Gut / Inflammation Research: KPV + gut-focused support
Tissue-Repair Research: KPV + BPC-157
Multi-Pathway Research: KPV + BPC-157 + GHK-Cu
Research Note: These combinations are discussed in research-use communities but have not been clinically validated as combination therapies.
Important Notes
Research on KPV is primarily preclinical, including laboratory and animal models of inflammation.
No standardized human dose, frequency, or cycle length has been established for injectable KPV.
Oral, topical, and injectable KPV are discussed in research settings, but evidence from one route should not automatically be applied to another.
Combination protocols involving KPV and other peptides have not been clinically validated in controlled human trials.
Important Disclaimer
KPV is not FDA-approved and is intended for research purposes only.
Research & References
Primary Research
- Getting SJ, Schiöth HB, Perretti M. Dissection of the Anti-Inflammatory Effect of the Core and C-Terminal (KPV) α-Melanocyte-Stimulating Hormone Peptides. Journal of Pharmacology and Experimental Therapeutics. 2003.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology. 2008.
- Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-Derived Tripeptide KPV Has Anti-Inflammatory Potential in Murine Models of Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2008.
- Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular Therapy. 2017.
- Land SC. Inhibition of Cellular and Systemic Inflammation Cues in Human Bronchial Epithelial Cells by Melanocortin-Related Peptides: Mechanism of KPV Action and a Role for MC3R Agonists. International Journal of Physiology, Pathophysiology and Pharmacology. 2012.
Reviews & Supporting Research
Research Note: The studies above establish KPV's anti-inflammatory activity across cellular, animal, and gut-barrier models. Specific self-administration dosing protocols described on this page are drawn from compounding-community practice and are not directly validated by the cited research.
Comments
Post a Comment